For the Inventor, By the Inventor

Enter assignee name

Horsham, PA, United States of America

Centocor Ortho Biotech Inc.

USPTO Granted Patents = 31

% Expired Patents = 51.6

CIPO Patents = 6

EPO Patents = 5

Trademarks = 3

Forward Citations = 342

Loading Chart...

Loading Chart...

71 inventors (with patents filed for the assignee):

Jill M Giles-Komar (7 out of 56 patents)

Karyn O'Neil (6 out of 39 patents)

Ronald Swanson (5 out of 17 patents)

4. Ellen Chi (4 out of 34 patents)

5. Michael Naso (4 out of 26 patents)

6. Mark Hilary Cunningham (4 out of 46 patents)

7. Bethany Swencki-Underwood (4 out of 6 patents)

8. Johan Fransson (3 out of 16 patents)

9. David M Knight (3 out of 101 patents)

10. David J Shealy (3 out of 41 patents)

11. Steven Jacobs (3 out of 42 patents)

12. Jill Carton (3 out of 17 patents)

13. Jacqueline Benson (3 out of 22 patents)

14. Raymond W Sweet (3 out of 47 patents)

15. Alexey Teplyakov (2 out of 32 patents)

Core Competencies:

Polynucleotides

Cysteine Proteases

Anti-CD147 Antibodies

Fusion Proteins

Bacterial Membrane Proteins

Anti-TNF Alpha

Hybridoma Fusion

Pluripotency Markers

Anti-IL-23 Antibodies

Immunoliposome Compositions

Pulmonary Fibrosis

Nucleic Acids

31 patents: Sort by Forward Citations

1. 8759067 - Polynucleotides encoding engineered plant cysteine proteases and their uses (2014-06-24),

2. 8728985 - Display of disulfide linked dimeric proteins in filamentous phage (2014-05-20),

3. 8618264 - Anti-CD147 antibodies, methods and uses (2013-12-31),

4. 8614185 - Fusion proteins of alpha-MSH derivatives and Fc (2013-12-24),

5. 8450086 - Bacterial membrane protein secretion (2013-05-28),

6. 8426186 - Engineered potato virus A nuclear inclusion protein (2013-04-23),

7. 8415291 - Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses (2013-04-09),

8. 8399630 - Engineered anti-IL-13 antibodies, compositions, methods and uses (2013-03-19),

9. RE43876 - Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm (2012-12-24),

10. 8338171 - Baboon homolog of human CD147 (2012-12-25),

11. 8323646 - Engineered anti-IL-13 antibodies, compositions, methods and uses (2012-12-04),

12. 8309688 - Monkey homolog of human oncostatin M and methods of use thereof (2012-11-13),

13. 8293482 - Fibronectin type III domain based scaffold compositions, methods and uses (2012-10-23),

14. 8278419 - Fibronectin type III domain based scaffold compositions, methods and uses (2012-10-02),

15. 8216842 - Enhancement of hybridoma fusion efficiencies through cell synchronization (2012-07-10),

Company Overview

Centocor Ortho Biotech Inc., based in Horsham, PA, is a biopharmaceutical company focused on the development and commercialization of innovative therapies for various medical conditions. The organization specializes in biologics, particularly monoclonal antibodies, targeting diseases such as autoimmune disorders and cancers. With a commitment to advancing healthcare, Centocor Ortho Biotech leverages cutting-edge research and technology to enhance patient outcomes and improve quality of life across diverse therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

31 Patents

#7 in Horsham, PA

#397 in Pennsylvania

#10,927 in US

#21,260 in the World

Horsham, PA, United States of America

Centocor Ortho Biotech Inc.

Forward Citations = 342

71 inventors:

Jill M Giles-Komar (7 out of 56 patents)

Karyn O'Neil (6 out of 39 patents)

Ronald Swanson (5 out of 17 patents)

4. Ellen Chi (4 out of 34 patents)

5. Michael Naso (4 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Centocor Ortho Biotech Inc.. Retrieved from https://idiyas.com/company/centocor-ortho-biotech

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…